CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Implementation of Inflation Reduction Act of 2022.
H.R.830 - HELP Copays Act.
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Duration: July 1, 2010
to
present
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Defense , Budget/Appropriations , Financial Institutions/Investments/Securities , Copyright/Patent/Trademark , Veterans , Food Industry (Safety, Labeling, etc.)
Spending: about $1,740,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Office of the Vice President of the United States, U.S. Senate,, House of Representatives,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox
Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on April 22.
Original Filing: 301575593.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Implementation of Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on Jan. 18.
Original Filing: 301529196.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Implementation of Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511904.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Implementation of Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301489625.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology and H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Implementation of Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301467243.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
Implementation of Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435746.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4373 - Further Additional Continuing Appropriations and Extensions Act, 2023 as it relates to FDA policy riders.
H.R.8299 - To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413221.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on July 19, 2022.
Original Filing: 301386143.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for California Life Sciences , earning $40,000. The report was filed on April 19, 2022.
Original Filing: 301363363.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Reauthorization of the Prescription Drug User Fee Act and related issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for California Life Sciences , earning $30,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331684.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.5376: Build Back Better Act, including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for California Life Sciences (FKA California Life Sciences Association) , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310638.xml
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
FY'22 Budget Reconciliation including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. And H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 19, 2021.
Original Filing: 301283275.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education around COVID-19 vaccines and therapeutics.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act.
H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to CovId-19 vaccines and TRIPS at WTO.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 20, 2021.
Original Filing: 301260727.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education around COVID-19 vaccines and therapeutics.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS rule on Medicare Coverage for Innovative Technology.
Education around legislative and regulatory efforts to impose a foreign reference pricing regime on pharmaceuticals and biologics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238614.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education around COVID-19 vaccines and therapeutics.
Administration Executive Order on International Drug Pricing.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222641.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education around COVID-19 vaccines and therapeutics.
Administration Executive Order on International Drug Pricing.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 20, 2020.
Original Filing: 301201617.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education around COVID-19 vaccines and therapeutics.
H.R.1425: Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2021 National Defense Authorization Act as it relates to the global pharmaceutical supply chain.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301176699.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128868.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1865: FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078391.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.2113: Prescription Drug STAR Act.
H.R.2296: FAIR Drug Pricing Act.
H.R.3: Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301056772.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R 269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.2113: Prescription Drug STAR Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301035119.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
S.344: Hatch-Waxman Integrity Act of 2019.
H.R 269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2207: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015926.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.184: Protect Medical Innovation Act and H.R.88 as it relates to the medical device tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985891.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.184: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300975662.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Reauthorization of PAHPA (Pandemic All Hazards Preparedness Act).
H.R.6: Support for Patients and Communities Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300950276.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
FY 2018 Continuing resolution as it relates to suspension of the medical device tax.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.
H.R.1625: Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929341.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R.3922: CHAMPIONING HEALTHY KIDS Act.
Education about the value of innovative new medicines.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
H.R.1/S.1: Tax Cuts and Jobs Act, as it relates to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915536.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R.1628: American Health Care Act and S. Better Care Reconciliation Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about the value of innovative new medicines.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
H.R.1645: Fostering Innovation Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300897316.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R.1628: American Health Care Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about the value of innovative new medicines.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
H.R.1645: Fostering Innovation Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
HHS rule related to expedited coverage of innovative technology.
Agencies Lobbied
Office of the Vice President of the United States
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 21, 2017.
Original Filing: 300878596.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R. 1628: American Health Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 184: Protect Medical Innovation Act.
Education about delays in application of the Research and Development Tax Credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848351.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program".
H.R. 34: 21st Century Cures Act conference report, specifically with respect to reforms at NIH and S. 1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program".
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R. 3299: Strengthening Public Health Emergency Response Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300835015.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program".
H.R. 6: 21st Century Cures Act and Senate HELP Committee Innovation effort to promote medical innovation for patients, specifically with respect to reforms at NIH.
Education about need for incentives for antibiotic development.
S.524: Comprehensive Addiction and Recovery Act of 2016, as it relates to Rx take back programs.
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R.3299: Strengthening Public Health Emergency Response Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 19, 2016.
Original Filing: 300815127.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
S.1878: Advancing Hope Act of 2016 - "To extend the pediatric priority review voucher program".
H.R. 6: 21st Century Cures Act and Senate HELP Committee Innovation effort to promote medical innovation for patients, specifically with respect to reforms at NIH.
Education about need for incentives for antibiotic development.
Education on Bayh-Dole Act as it relates to "march in rights" at NIH.
S.524: Comprehensive Addiction and Recovery Act of 2016, as it relates to Rx take back programs.
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R.3299: Strengthening Public Health Emergency Response Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY 2017 Financial Services Appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on April 20, 2016.
Original Filing: 300803047.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 6: 21st Century Cures Act and Senate HELP Committee Innovation effort to promote medical innovation for patients, specifically with respect to reforms at NIH.
Education on Bayh-Dole Act as it relates to "march in rights" at NIH.
S.524: Comprehensive Addiction and Recovery Act of 2016, as it relates to Rx take back programs.
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R. 3513/S. 2023: Prescription Drug Affordability Act of 2015.
H.R.3299: Strengthening Public Health Emergency Response Act of 2015.
Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776307.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 6: 21st Century Cures Act and Senate HELP Committee companion effort to promote medical innovation for patients, specifically with respect to reforms at NIH.
Education about the value of innovative new medicines.
Education about FDA performance on review of drugs and medical devices.
H.R. 3513/S. 2023: Prescription Drug Affordability Act of 2015.
Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and provisions related to delay in the medical device tax.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763598.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 6: 21st Century Cures Act and Senate HELP Committee companion effort to promote medical innovation for patients, specifically with respect to reforms at NIH and Brat floor amendment dealing with NIH funding.
Education about the value of innovative new medicines.
Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for California Life Sciences Association , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300743474.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 6: 21st Century Cures Act and Senate HELP Committee companion effort to promote medical innovation for patients, specifically with respect to reforms at NIH.
Education about the value of innovative new medicines.
Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 160: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for California Life Sciences Association (Formerly California Healthcare Institute) , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300718820.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 5771: Tax Increase Prevention Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700311.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.Education about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 5771: Tax Increase Prevention Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684694.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.Education about the importance of adequate funding for NIH.
Education about the value of innovations in Hepatitis C treatment.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 4438: American Research and Competitiveness Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on July 14, 2014.
Original Filing: 300664624.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.Educated about the importance of adequate funding for NIH.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 4438: American Research and Competitiveness Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4810: Veteran Access to Care Act of 2014.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on April 14, 2014.
Original Filing: 300635673.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 4302: Protecting Access to Medicare Act of 2014.
H.R. 4160: Keep the Promise to Seniors Act of 2014.
CMS proposed rule affecting the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) Programs, specifically as it relates to changes to the Part D programs, including coverage of therapeutic classes and non interference.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309: Innovation Act.
S. 1720: Patent Transparency and Improvements Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621913.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Monitored implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 3742: Antibiotic Development to Advance Patient Treatment Act of 2013.
H.R. 2725: Food and Drug Administration Safety Over Sequestration Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2810, S: Medicare Patient Access and Quality Improvement Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.J. Res. 59 The Bipartisan Budget Act of 2013 Public Law No: 113-067.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3309: Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Oct. 18, 2013.
Original Filing: 300607593.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.H.R. 3089: Compounding Clarity Act of 2013.
H.R. 3024: The Drug Quality and Security Act.
H.R. 2725: Food and Drug Administration Safety Over Sequestration Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on July 15, 2013.
Original Filing: 300577196.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.H.R.2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act - as it relates to sequestration of drug and device user fees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on April 18, 2013.
Original Filing: 300558904.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 2405: Pandemic and All-Hazards Preparedness Reauthorization Act of 2013.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
H.R. 351: Legislation to repeal the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 523: Protect Medical Innovation Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Jan. 14, 2013.
Original Filing: 300536609.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
H.R. 2405: Pandemic and All-Hazards Preparedness Reauthorization Act of 2011.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 436: Health Care Cost Reduction Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Oct. 16, 2012.
Original Filing: 300512495.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012 as it relates to reform of the drug and device approval process and legislative initiatives as well as tracking of FDA performance data, and provisions providing incentives for development of new antibiotics (H.R. 2182: GAIN ACT).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 436: Health Care Cost Reduction Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.J.Res. 117: Continuing Appropriations Resolution for Fiscal Year 2013.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on July 20, 2012.
Original Filing: 300494134.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Educated staff on advances in diabetes research and discussed opportunities for further briefing with Congressional Diabetes Caucus.
H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012 -- issues related to reform of the drug and device approval process and legislative initiatives as well as tracking of FDA performance data, and provisions providing incentives for development of new antibiotics (H.R. 2182: GAIN ACT).
Educated staff about analysis of data related to the drug and device approval process at FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 436: Health Care Cost Reduction Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on April 4, 2012.
Original Filing: 300464006.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
Educated staff on advances in diabetes research and discussed opportunities for further briefing with Congressional Diabetes Caucus.
FDA Reform Issues related to reform of the drug and device approval process and legislative initiatives around the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017 as well as the Medical Device User Fee Act Modernization Act reauthorization for FY 2013-2017.
FDA Reform bills to streamline and improve the drug and device approval processes.
H.R. 3203: Novel Device Regulatory Relief Act of 2011.
H.R. 3204: Guidance Accountability and Transparency Act of 2011.
H.R. 3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011.
H.R. 3208: Patients Come First Act of 2011.
H.R. 3209: Premarket Predictability Act of 2011.
H.R. 3230: Keeping America Competitive Through Harmonization Act of 2011.
Educated staff about analysis of data related to the drug and device approval process at FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Monitored H.R. 3630: Temporary Payroll Tax Cut Continuation Act of 2011 as it relates to Medicare reimbursement for Part B drugs.H.R. 5: Help Efficient, Accessible, Low-Cost, Timely Healthcare Act.
H.R. 452: Medicare Decisions Accountability Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 436: Protect Medical Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Jan. 18, 2012.
Original Filing: 300445589.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
FDA Reform Issues related to reform of the drug and device approval process and legislative initiatives around the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017 as well as the Medical Device User Fee Act Modernization Act reauthorization for FY 2013-2017.FDA Reform bills to streamline and improve the drug and device approval processes.
H.R. 3203: Novel Device Regulatory Relief Act of 2011.
H.R. 3204: Guidance Accountability and Transparency Act of 2011.
H.R. 3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011.
H.R. 3208: Patients Come First Act of 2011.
H.R. 3209: Premarket Predictability Act of 2011.
H.R. 3230: Keeping America Competitive Through Harmonization Act of 2011.
Educated staff about analysis of data related to the drug and device approval process at FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D program.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs.H.R. 3630/3765: Temporary Payroll Tax Cut Continuation Act of 2011 as they relate to Medicare reimbursement for Part B drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Oct. 20, 2011.
Original Filing: 300423992.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
FDA Reform Issues related to reform of the drug and device approval process.
Educated staff about analysis of data related to the drug and device approval process at FDA.
S.17 - Medical Device Access and Innovation Act.H.R. 436 - Protect Medical Device Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals to impose mandatory rebates in the Part D program.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on July 19, 2011.
Original Filing: 300399048.xml
Lobbying Issues
Promoted life sciences community and communicated economic and health benefits of the industry.
FDA Reform Issues related to reform of the 510(k) approval process.
Educated staff about analysis of data related to the drug and device approval process at FDA.
S.17 - Medical Device Access and Innovation Act.H.R. 436 - Protect Medical Device Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Patent Reform.
H.R. 1249 - America Invents Act of 2011.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on April 19, 2011.
Original Filing: 300369569.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars, and a tax on medical device manufacturers.
Educated staff on health complications from sleep apnea disorder.
Promoted life sciences community and communicated economic and health benefits of the industry.FDA Reform Issues including issues related to reform of the 510(k) approval process.
Educated staff about analysis of data related to the drug and device approval process at FDA.
S. 17 - Medical Device Access and Innovation Act
H.R. 436 - Protect Medical Device Innovation Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Patent Reform
S.23 - America Invents Act of 2011
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Jan. 19, 2011.
Original Filing: 300346594.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Educated staff on health complications from sleep apnea disorder.
Promoted life sciences community and communicated economic and health benefits of the industry.FDA Reform Issues including issues related to reform of the 510(k) approval process.
Educated staff about analysis of data related to the drug and device approval process at FDA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for California Healthcare Institute , earning $30,000. The report was filed on Oct. 15, 2010.
Original Filing: 300321272.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Educated staff on health complications from sleep apnea disorder.
Promoted life sciences community and communicated economic and health benefits of this industry.FDA Reform Issues including issues related to reform of the 510(k) approval process.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2010
W Strategies, LLC filed a lobbying registration on Aug. 9, 2010 to represent California Healthcare Institute, effective July 1, 2010.
Original Filing: 300306723.xml
Issue(s) they said they’d lobby about: Implementation of PPACA, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars. Promote life sciences community and communicate economic and health benefits of this industry.
Monitor legislation related to Patent Reform.
FDA Reform Issues. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate